Chemical Structure : Batiraxcept
货号: PC-38856Not For Human Use, Lab Use Only.
Batiraxcept (AVB‐S6‐500, AVB-500) is a first-in-class Fc fusion protein of the extracellular domain of AXL that binds the GAS6 ligand thereby inhibiting AXL signaling.
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Batiraxcept (AVB‐S6‐500, AVB-500) is a first-in-class Fc fusion protein of the extracellular domain of AXL that binds the GAS6 ligand thereby inhibiting AXL signaling.
Batiraxcept (AVB‐S6‐500, AVB-500) neutralized growth arrest-specific 6 (GAS6) protein and effectively inhibited AXL signaling in preclinical cancer models.
ABatiraxcept (AVB‐S6‐500, AVB-500) binds GAS6 with low femtomolar range affinity to effectively bind GAS6 and eliminate its ability to stimulate the AXL pathway.
Human tyrosine-protein kinase receptor UFO (AXL oncogene) fragment (8-202, 1-195 in the current sequence), variant (G14>S7, A54>V47, D69>G62, V74>A67, G109>R102), fused via peptidyl linker (196GGGGS200) to a human immunoglobulin G1 Fc fragment (201-426, C-terminal Lys residue deleted), dimer, glycosylated, produced in Chinese hamster ovary (CHO) cells.
分子量 | ||
分子式 | ||
外观性状 | Solid | |
储存条件 |
|
|
Solubility |
10 mM in DMSO |
1. Bonifacio L, et al. Clin Transl Sci. 2020 Jan;13(1):204-211.
2. Mullen MM, et al. Mol Cancer Res. 2022 Feb;20(2):265-279.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright